Epic Bio
Main focus: CRISPR-based epigenetic engineering
Company stage: Pre-clinical
Diseases (gene editing): Facioscapulohumeral Muscular Dystrophy (FSHD), Heterozygous Familial Hypercholesterolemia (HeFH), Alpha-1 Antitrypsin Deficiency (A1AD), Retinitis Pigmentosa 4 (RP4), Retinitis Pigmentosa 11 (RP11)
Genome editing tool: CRISPR activation/CRISPR inhibition
Funding stage: Private
Location: South San Francisco, CA, USA
Website: https://epic-bio.com/
Pipeline: https://epic-bio.com/pipeline/
Epic Bio is a start-up company focused on epigenetic engineering using the CRISPR-Cas system. The company holds an exclusive license to a Cas enzyme called CasMINI, which is the smallest and most deliverable dCas protein to date, which can then be engineered with a modulating protein to attain activating- or inhibitory effects.